Early Access — free while we kick the tires
EdgarHawk

Rickenbach Josef H Von

Director

Director

Latest: Director buying · May 2026

1 filing analyzed · 1 company · Latest 2026-05-28
Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗

Companies

Company Buys Sells Direction
Rein Therapeutics, Inc. RNTX 4 0 Net buying

Activity

May 2026
high
Buy
47,060 shares
$49,561
Significance 6/10

Director Von Rickenbach purchases 47,060 shares at $1.04–$1.07 (avg $1.05), tripling holdings to 62.5K shares amid -49.8% drawdown from 52-week high.

Rickenbach Josef H Von, a Director at unprofitable RNTX, executed 4 separate purchases totaling 47,060 shares for $49,560.64 between May 21–27, 2026, at prices ranging from $1.04 to $1.07. This increased his holdings by 304.5% from 15,454 to 62,514 shares. The stock is currently trading at $1.11, representing a -49.8% decline from its 52-week high of $2.21 and a -23.4% drop over the prior 30 days. The company posted $0.00 quarterly revenue and -$5.8M net income, with negative full-year profitability. The magnitude of the purchase relative to prior holdings and the execution across multiple trading days warrants attention to whether this reflects a strategic reassessment or other material considerations.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access